Deutsche Bank
IKT icon

Deutsche Bank’s Inhibikase Therapeutics IKT Stock Holding History

Deutsche Bank’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
126,677
+4,235
+3% +$7.58K ﹤0.01% 3124
2026
Q1 		$206K Buy
122,442
+67,533
+123% +$120K ﹤0.01% 2995
2025
Q4 		$113K Sell
54,909
-25,587
-32% -$40.7K ﹤0.01% 3258
2025
Q3 		$130K Buy
+80,496
New +$139K ﹤0.01% 3253

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank's IKT Position: Q2 2026 in Review

Deutsche Bank increased its Inhibikase Therapeutics (IKT) stake by 3.5% in Q2 2026, buying an estimated $7.58K and bringing the position to 126,677 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #3124.

Deutsche Bank first reported a position in IKT in Q3 2025 and has held it in 4 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Deutsche Bank held 126,677 shares of Inhibikase Therapeutics worth $257K as of Q2 2026.
  • Deutsche Bank bought 4,235 Inhibikase Therapeutics shares in Q2 2026, an estimated $7.58K.
  • Inhibikase Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3124 holding.
  • Deutsche Bank first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.